Prosecution Insights
Last updated: August 16, 2026

Cedars-Sinai Medical Center

27 pending office actions • 19 art units • 26 examiners • 0 of 27 (0%) have an AI response strategy ready • 33 patents granted in the last 365 days

Portfolio Summary

27
Total Pending OAs
19
Non-Final OAs
8
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
1
Due this week
0
Due this month
3
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 7 days (1)Due ≤ 60 days (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

12
Hard (44%)
9
Medium (33%)
5
Easy (19%)
1
Unknown (4%)

Rejection Statute Mix

BucketCases
§101 + other5 (19%)
§103 only9 (33%)
§112 only3 (11%)
Double-patenting only2 (7%)
Multi-statute (no §101)7 (26%)
No statute on record1 (4%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

20
Life Sciences
74% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
4
Mechanical / Eng
15% of docket
3
Business / Other
11% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

270 h
Manual time on pending OAs
54 h
Time saved (low, 20%)
94 h
Time saved (mid, 35%)
2.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BRETZ, COREY LANE 2 0.0% +0.0%
NGUYEN, HIEP VAN 1 55.2% +29.5%
CHU, RANDOLPH I 1 80.4% +6.1%
WILDER, CYNTHIA B 1 71.0% +26.7%
ABOUELELA, MAY A 1 75.2% +36.3%
NG, JONATHAN K 1 35.6% +13.7%
KENYON, JOHN S 1 80.2% +17.5%
HINES, JANA A 1 53.0% +39.6%
STEPHENS, AMELIA CAROLE 1 80.0% +50.0%
MONTANARI, DAVID A 1 64.8% +49.2%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18931723 STORAGE, DISPLAY, AND ANALYSIS OF FACTORED MULTIDIMENSIONAL IMAGES CHU, RANDOLPH I

Hard Cases (13)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18350077 METHODS AND FORMULATIONS FOR GENE THERAPY, AND FOR COMBINING GENE THERAPY WITH DITPA TREATMENT, OF ALLAN-HERNDON-DUDLEY SYNDROME BRETZ, COREY LANE 6d
18546947 ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG STEPHENS, AMELIA CAROLE 50d
19123191 METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS NGUYEN, HIEP VAN
18647340 RADIOGENOMIC SIGNATURES IN BLADDER CANCER PATIENTS AND USES THEREOF WILDER, CYNTHIA B
18695144 DAILY FASTING METHANE TO DETECT INTESTINAL METHANOGEN OVERGROWTH AND MONITOR TREATMENT RESPONSE ABOUELELA, MAY A
18580962 METHODS AND SYSTEMS FOR EARLY DETECTION OF OCULAR AND/OR NEUROLOGICAL CONDITIONS NG, JONATHAN K
18571924 THERAPEUTIC NUCLEIC ACIDS AND METHODS OF USE THEREOF BRETZ, COREY LANE
18267408 INTRA-RENAL INFUSIONS OF C1 INHIBITOR PRIOR TO TRANSPLANTATION OF ALLOGRAFTS TO REDUCE DELAYED GRAFT FUNCTION AND ISCHEMIA/REPERFUSION INJURY AND TO IMPROVE LONG-TERM GRAFT FUNCTION D' AMBROSIO, THEA

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18530467 COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS KENYON, JOHN S 34d
18546947 ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG STEPHENS, AMELIA CAROLE 50d
19123191 METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS NGUYEN, HIEP VAN
18647340 RADIOGENOMIC SIGNATURES IN BLADDER CANCER PATIENTS AND USES THEREOF WILDER, CYNTHIA B
18695144 DAILY FASTING METHANE TO DETECT INTESTINAL METHANOGEN OVERGROWTH AND MONITOR TREATMENT RESPONSE ABOUELELA, MAY A
18580962 METHODS AND SYSTEMS FOR EARLY DETECTION OF OCULAR AND/OR NEUROLOGICAL CONDITIONS NG, JONATHAN K
18386537 METHODS FOR TREATING NEPHROTIC SYNDROME HINES, JANA A
18268822 METHODS FOR DIFFERENTIATION OF PANCREATIC EXOCRINE CELLS FROM HUMAN INDUCED PLURIPOTENT STEM CELLS MONTANARI, DAVID A

Top Art Units

Art UnitApps
1645 2
1632 2
1654 2
1634 2
1642 2
3686 1
3791 1
3619 1
1625 1
1635 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19123191 METHODS AND SYSTEMS OF MULTI-OMIC APPROACH FOR MOLECULAR PROFILING OF TUMORS NGUYEN, HIEP VAN 3686 §101§103§112 Non-Final OA Pending Apr 22, 2025
18931723 STORAGE, DISPLAY, AND ANALYSIS OF FACTORED MULTIDIMENSIONAL IMAGES CHU, RANDOLPH I DP Non-Final OA Pending Oct 30, 2024
18647340 RADIOGENOMIC SIGNATURES IN BLADDER CANCER PATIENTS AND USES THEREOF WILDER, CYNTHIA B §103§112 Non-Final OA Pending Apr 26, 2024
18695144 DAILY FASTING METHANE TO DETECT INTESTINAL METHANOGEN OVERGROWTH AND MONITOR TREATMENT RESPONSE ABOUELELA, MAY A 3791 §101§103§112 Non-Final OA Pending Mar 25, 2024
18580962 METHODS AND SYSTEMS FOR EARLY DETECTION OF OCULAR AND/OR NEUROLOGICAL CONDITIONS NG, JONATHAN K 3619 §101§103 Final Rejection Pending Jan 19, 2024
18571924 THERAPEUTIC NUCLEIC ACIDS AND METHODS OF USE THEREOF BRETZ, COREY LANE §101§102§103§112DP Non-Final OA Pending Dec 19, 2023
18530467 COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS KENYON, JOHN S 1625 Other Non-Final OA 34d Pending Dec 06, 2023
18386537 METHODS FOR TREATING NEPHROTIC SYNDROME HINES, JANA A 1645 §103 Non-Final OA Pending Nov 02, 2023
18546947 ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG STEPHENS, AMELIA CAROLE 1645 §102§103§112Other Non-Final OA 50d Pending Aug 17, 2023
18350077 METHODS AND FORMULATIONS FOR GENE THERAPY, AND FOR COMBINING GENE THERAPY WITH DITPA TREATMENT, OF ALLAN-HERNDON-DUDLEY SYNDROME BRETZ, COREY LANE 1635 DP Final Rejection 6d Pending Jul 11, 2023
18268822 METHODS FOR DIFFERENTIATION OF PANCREATIC EXOCRINE CELLS FROM HUMAN INDUCED PLURIPOTENT STEM CELLS MONTANARI, DAVID A 1632 §112 Non-Final OA Pending Jun 21, 2023
18267408 INTRA-RENAL INFUSIONS OF C1 INHIBITOR PRIOR TO TRANSPLANTATION OF ALLOGRAFTS TO REDUCE DELAYED GRAFT FUNCTION AND ISCHEMIA/REPERFUSION INJURY AND TO IMPROVE LONG-TERM GRAFT FUNCTION D' AMBROSIO, THEA 1654 §102§103§112 Non-Final OA Pending Jun 14, 2023
18320653 Methods for Detecting and Treating Irritable Bowel Syndrome STOICA, ELLY GERALD 1647 §112Other Non-Final OA 43d overdue Pending May 19, 2023
17924010 DEVICES, ASSAYS AND METHODS OF TESTING PREECLAMPSIA GIERE, REBECCA M 1677 §102§103§112 Non-Final OA Pending Nov 08, 2022
17921217 MULTI-LINEAGE CARDIOVASCULAR MICROFLUIDIC ORGAN-CHIP DHAR, MATASHA 1632 §102§103§112 Non-Final OA Pending Oct 25, 2022
17921174 ISOLATION AND FUNCTIONAL ANALYSIS OF EPITHELIAL PROGENITOR CELLS FROM THE HUMAN LUNG ABBOTT, KODYE LEE 1634 §103§112 Non-Final OA Pending Oct 25, 2022
17912809 INTERNAL ULTRAVIOLET THERAPY HOLMES, REX R 3796 §103 Non-Final OA Pending Sep 19, 2022
17912227 PREVENTION AND INTERVENTION OF INFARCT EXPANSION FOLLOWING HEMORRHAGIC INFARCTIONS VALLE, ERNESTO 1623 §103 Non-Final OA Pending Sep 16, 2022
17779716 COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION AEDER, SEAN E 1642 §102§103§112 Final Rejection Pending May 25, 2022
17766706 MESH CHOPPING OF NEURAL PROGENITOR CELL AGGREGATES ABUZEINEH, HANAN ISAM 1633 §103 Final Rejection 73d overdue Pending Apr 05, 2022
17633505 METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY WEHBE, ANNE MARIE SABRINA 1634 §103 Final Rejection Pending Feb 07, 2022
17633067 METHODS OF IMPROVING ORGAN FUNCTION AUDET, MAURY A 1654 §103 Final Rejection Pending Feb 04, 2022
17565834 METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS FERNANDEZ, SUSAN EMILY 1651 §112 Final Rejection 112d overdue Pending Dec 30, 2021
17435159 ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANTS STONEBRAKER, ALYSSA RAE 1642 §103 Non-Final OA 31d overdue Pending Aug 31, 2021
17266488 COMPOSITIONS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASES LADD, CAROLYN LOUISE 1622 §103Other Final Rejection 56d Pending Feb 05, 2021
17043888 METHODS FOR IN VITRO EXPANSION OF ADULT TISSUE STEM CELLS GONZALES, JOSEPHINE MARIA 1631 §103 Non-Final OA Pending Sep 30, 2020
16515458 HIGHLY MULTIPLEXED AND MASS SPECTROMETRY BASED METHODS TO MEASURING 72 HUMAN PROTEINS MARTIN, PAUL C 1653 §101§103§112 Non-Final OA Pending Jul 18, 2019

Managing Cedars-Sinai Medical Center's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month